Top

European Journal of Medical Research

Published in:

Open Access 01-12-2023 | Lung Cancer | Research

Correlation analysis of clinical, pathological, imaging and genetic features of ground-glass nodule featured lung adenocarcinomas between high-risk and non-high-risk individuals

Authors: Jing Ren, Yuan Wang, Chunrong Liu, Lan Yang, Xinlu Men, Zhixin Qiu

Published in: European Journal of Medical Research | Issue 1/2023

Abstract

Background

Early stage lung adenocarcinomas manifested as ground-glass nodules (GGNs) are increasingly being detected, but screening and diagnosis for GGN-featured lung adenocarcinomas in different risk populations reach no agreement.

Objectives

To analyze the clinical, pathological, imaging and genetic features of GGN-featured lung adenocarcinomas on high-resolution computed tomography (HRCT) in different risk groups.

Methods

Include patients with GGNs on HRCT surgically diagnosed as lung adenocarcinoma in the West China Hospital, Sichuan University from 2009 to 2021, and their clinical, pathological, imaging and gene sequencing data.

Results

According to Chinese Expert Consensus on Screening and Management of Lung Cancer, 1,800 patients with GGN-featured lung adenocarcinoma, 545 males (incl. 269 smokers) and 1,255 females (incl. 16 smokers), were divided into high-risk (509) and non-high-risk (1,291) groups. Among them, 1,095 were detected via physical examination. The mean age at diagnosis was 54.78 (23–84) and the mean time from detection to diagnosis was 9.59 months. There were more males than females in the high-risk group [288 (56.58%) vs 221 (43.42%)], just the opposite in the non-high-risk group [1,034 (80.09%) vs 257 (19.91%)] (both P < 0.001). No statistical difference was found in GGN detection way (P > 0.05). The frequency of invasive adenocarcinoma was higher in the high-risk group, while those of precursor lesions and minimally invasive adenocarcinoma were higher in the non-high-risk group (all P < 0.001). The preoperative follow-up time in the non-high-risk group was shorter (P < 0.05). A total of 711 gene mutations were observed in 473 patients with a ratio of non-high-risk to high-risk of 494:217. The incidence of EGFR mutation was not statistically significant (P = 0.824), while those of TP53 and KRAS mutations were higher in the high-risk group (P < 0.05).

Conclusions

GGN-featured lung adenocarcinoma is dominated by non-high-risk female patients. Shorter preoperative follow-up in the non-high-risk group and no statistical difference in GGN detection way suggests the existing screening criteria for high-risk population may not suit GGN-featured lung cancer. In addition, the incidences of KRAS and TP53 mutations are higher in the high-risk group.

Available only for authorised users

Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32. https://doi.org/10.3322/caac.21338.CrossRefPubMed

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. https://doi.org/10.3322/caac.21660.CrossRefPubMed

Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395–409. https://doi.org/10.1056/NEJMoa1102873.CrossRefPubMed

Wood DE, Kazerooni E, Baum SL, Dransfield MT, Eapen GA, Ettinger DS, et al. Lung cancer screening, version 1.2015: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2015;13:23–34. https://doi.org/10.6004/jnccn.2015.0006.CrossRefPubMed

Smith RA, Manassaram-Baptiste D, Brooks D, Doroshenk M, Fedewa S, Saslow D, et al. Cancer screening in the United States, 2015: a review of current American cancer society guidelines and current issues in cancer screening. CA Cancer J Clin. 2015;65:30–54. https://doi.org/10.3322/caac.21261.CrossRefPubMed

Chinese Alliance Against Lung Cancer, Chinese Medical Association of Respiratory Disease Branch Lung Cancer Study Group, Committee CMDAoRDBLCW. Chinese expert consensus on screening and management of lung cancer (in Chinese). Int J Respir. 2019;39:1604–15. https://doi.org/10.3760/cma.j.issn.1673-436X.2019.21.002.CrossRef

Zhang Y, Jheon S, Li H, Zhang H, Xie Y, Qian B, et al. Results of low-dose computed tomography as a regular health examination among Chinese hospital employees. J Thorac Cardiovasc Surg. 2020;160:824-831.e824. https://doi.org/10.1016/j.jtcvs.2019.10.145.CrossRefPubMed

Godoy MCB, Odisio E, Truong MT, de Groot PM, Shroff GS, Erasmus JJ. Pulmonary nodule management in lung cancer screening a pictorial review of Lung-RADS version 1.0. Radiol Clin North Am. 2018;56:353. https://doi.org/10.1016/j.rcl.2018.01.003.CrossRefPubMed

Nicholson AG, Tsao MS, Beasley MB, Borczuk AC, Brambilla E, Cooper WA, et al. The 2021 WHO classification of lung tumors: impact of advances since 2015. J Thorac Oncol. 2022;17:362–87. https://doi.org/10.1016/j.jtho.2021.11.003.CrossRefPubMed

10.

Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WEE, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (Eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11:39–51. https://doi.org/10.1016/j.jtho.2015.09.009.CrossRefPubMed

11.

Oudkerk M, Liu SY, Heuvelmans MA, Walter JE, Field JK. Lung cancer LDCT screening and mortality reduction - evidence, pitfalls and future perspectives. Nat Rev Clin Oncol. 2021;18:135–51. https://doi.org/10.1038/s41571-020-00432-6.CrossRefPubMed

12.

Migliore M, Fornito M, Palazzolo M, Criscione A, Gangemi M, Borrata F, et al. Ground glass opacities management in the lung cancer screening era. Ann Transl Med. 2018;6:90. https://doi.org/10.21037/atm.2017.07.28.CrossRefPubMedPubMedCentral

13.

Gao JW, Rizzo S, Ma LH, Qiu XY, Warth A, Seki N, et al. Pulmonary ground-glass opacity: computed tomography features, histopathology and molecular pathology. Transl Lung Cancer Res. 2017;6:68–75. https://doi.org/10.21037/tlcr.2017.01.02.CrossRefPubMedPubMedCentral

14.

Song YS, Park CM, Park SJ, Lee SM, Jeon YK, Goo JM. Volume and mass doubling times of persistent pulmonary subsolid nodules detected in patients without known malignancy. Radiology. 2014;273:276–84. https://doi.org/10.1148/radiol.14132324.CrossRefPubMed

15.

Heidinger BH, Anderson KR, Nemec U, Costa DB, Gangadharan SR, VanderLaan PA, et al. Lung adenocarcinoma manifesting as pure ground-glass nodules: correlating CT Size, volume, density, and roundness with histopathologic invasion and size. J Thorac Oncol. 2017;12:1288–98. https://doi.org/10.1016/j.jtho.2017.05.017.CrossRefPubMed

16.

Yankelevitz DF, Henschke CI. Overdiagnosis in lung cancer screening. Transl Lung Cancer Res. 2021;10:1136–40. https://doi.org/10.21037/tlcr-20-736.CrossRefPubMedPubMedCentral

17.

National Lung Screening Trial Research Team. Lung cancer incidence and mortality with extended follow-up in the national lung screening trial. J Thorac Oncol. 2019;14:1732–42. https://doi.org/10.1016/j.jtho.2019.05.044.CrossRef

18.

Moyer VA. Screening for lung cancer: U.S. preventive services task force recommendation statement. Ann Intern Med. 2014;160:330–8. https://doi.org/10.7326/m13-2771.CrossRefPubMed

19.

Nair VS. Management of lung nodules detected by volume CT scanning. N Engl J Med. 2010;362:757–757.CrossRefPubMed

20.

Lu H, Mu W, Balagurunathan Y, Qi J, Abdalah MA, Garcia AL, et al. Multi-window CT based Radiomic signatures in differentiating indolent versus aggressive lung cancers in the National Lung Screening Trial: a retrospective study. Cancer Imaging. 2019. https://doi.org/10.1186/s40644-019-0232-6.CrossRefPubMedPubMedCentral

21.

Chen WQ, Li N, Shi JF, Ren JS, Chen HD, Li J, et al. Progress of cancer screening program in Urban China (in Chinese). China Cancer. 2019;28:23–5. https://doi.org/10.11735/j.issn.1004-0242.2019.01.A003.CrossRef

22.

Chen WQ, Cao MM. Strengthening cancer early diagnosis and treatment, implementing the strategy of healthy China (in Chinese). China Cancer. 2019;28:643–5. https://doi.org/10.11735/j.issn.1004-0242.2019.09.A001.CrossRef

23.

She J, Yang P, Hong QY, Bai CX. Lung cancer in China challenges and interventions. Chest. 2013;143:1117–26. https://doi.org/10.1378/chest.11-2948.CrossRefPubMed

24.

Chen WQ, Zheng RS, Zeng HM, Zhang SW. Epidemiology of lung cancer in China. Thorac Cancer. 2015;6:209–15. https://doi.org/10.1111/1759-7714.12169.CrossRefPubMedPubMedCentral

25.

Zhou YD, Chen ZW, Chen HQ. Lung cancer screening strategy for non-high-risk population (in Chinese). China Oncol. 2020;30:726–32. https://doi.org/10.19401/j.cnki.1007-3639.2020.10.002.CrossRef

26.

Ren J, Chen F, Liu Q, Zhou Y, Cheng Y, Tian P, et al. Management of pulmonary nodules in non-high-risk population: initial evidence from a real-world prospective cohort study in China. Chin Med J (Engl). 2022;135:994–6. https://doi.org/10.1097/cm9.0000000000001848.CrossRefPubMed

27.

Harrison PT, Vyse S, Huang PH. Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. Semin Cancer Biol. 2020;61:167–79. https://doi.org/10.1016/j.semcancer.2019.09.015.CrossRefPubMedPubMedCentral

28.

Shi Y, Au JS, Thongprasert S, Srinivasan S, Tsai CM, Khoa MT, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014;9:154–62. https://doi.org/10.1097/jto.0000000000000033.CrossRefPubMedPubMedCentral

29.

Xue X, Asuquo I, Hong L, Gao J, Dong Z, Pang L, et al. Catalog of lung cancer gene mutations among Chinese patients. Front Oncol. 2020;10:1251. https://doi.org/10.3389/fonc.2020.01251.CrossRefPubMedPubMedCentral

30.

Pi C, Xu CR, Zhang MF, Peng XX, Wei XW, Gao X, et al. EGFR mutations in early-stage and advanced-stage lung adenocarcinoma: analysis based on large-scale data from China. Thorac Cancer. 2018;9:814–9. https://doi.org/10.1111/1759-7714.12651.CrossRefPubMedPubMedCentral

31.

Ren Y, Yao Y, Ma Q, Zhong D. EGFR gene-mutation status correlated with therapeutic decision making in lung adenocarcinoma. Onco Targets Ther. 2015;8:3017–20. https://doi.org/10.2147/ott.S87146.CrossRefPubMedPubMedCentral

32.

Shi J, Hua X, Zhu B, Ravichandran S, Wang M, Nguyen C, et al. Somatic genomics and clinical features of lung adenocarcinoma: a retrospective study. PLoS Med. 2016;13:e1002162. https://doi.org/10.1371/journal.pmed.1002162.CrossRefPubMedPubMedCentral

33.

Ye XH, Bu ZB, Feng J, Peng L, Liao XB, Zhu XL, et al. Association between the TP53 polymorphisms and lung cancer risk: a meta-analysis. Mol Biol Rep. 2014;41:373–85. https://doi.org/10.1007/s11033-013-2871-1.CrossRefPubMed

34.

Neumann MP, Gonzalez MV, Pitiot AS, Santamaria I, Martinez C, Tardon A, et al. TP53 p. R72P genotype is a marker of poor prognosis in lung cancer. Cancer Biomark. 2018;21:747–54. https://doi.org/10.3233/cbm-170230.CrossRefPubMed

35.

Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502:333–9. https://doi.org/10.1038/nature12634.CrossRefPubMedPubMedCentral

36.

Zhao Y, Varn FS, Cai G, Xiao F, Amos CI, Cheng C. A P53-deficiency gene signature predicts recurrence risk of patients with early-stage lung adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2018;27:86–95. https://doi.org/10.1158/1055-9965.Epi-17-0478.CrossRefPubMed

37.

Blakely CM, Watkins TBK, Wu W, Gini B, Chabon JJ, McCoach CE, et al. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nat Genet. 2017;49:1693–704. https://doi.org/10.1038/ng.3990.CrossRefPubMedPubMedCentral

38.

Del Re M, Rofi E, Restante G, Crucitta S, Arrigoni E, Fogli S, et al. Implications of KRAS mutations in acquired resistance to treatment in NSCLC. Oncotarget. 2018;9:6630–43. https://doi.org/10.18632/oncotarget.23553.CrossRefPubMed

39.

Kim HR, Ahn JR, Lee JG, Bang DH, Ha SJ, Hong YK, et al. The impact of cigarette smoking on the frequency of and qualitative differences in KRAS mutations in Korean patients with lung adenocarcinoma. Yonsei Med J. 2013;54:865–74. https://doi.org/10.3349/ymj.2013.54.4.865.CrossRefPubMedPubMedCentral

40.

Boch C, Kollmeier J, Roth A, Stephan-Falkenau S, Misch D, Gruning W, et al. The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from a cohort study. BMJ Open. 2013. https://doi.org/10.1136/bmjopen-2013-002560.CrossRefPubMedPubMedCentral

41.

Choi Y, Kim KH, Jeong BH, Lee KJ, Kim H, Kwon OJ, et al. Clinicoradiopathological features and prognosis according to genomic alterations in patients with resected lung adenocarcinoma. J Thorac Dis. 2020;12:5357–68. https://doi.org/10.21037/jtd-20-1716.CrossRefPubMedPubMedCentral

42.

Kobayashi Y, Mitsudomi T, Sakao Y, Yatabe Y. Genetic features of pulmonary adenocarcinoma presenting with ground-glass nodules: the differences between nodules with and without growth. Ann Oncol. 2015;26:156–61. https://doi.org/10.1093/annonc/mdu505.CrossRefPubMed

43.

Ying M, Zhu X, Chen K, Sha Z, Chen L. Should KRAS mutation still be used as a routine predictor of response to EGFR-TKIs in advanced non-small-cell lung cancer? A revaluation based on meta-analysis. J Cancer Res Clin Oncol. 2015;141:1427–39. https://doi.org/10.1007/s00432-015-1910-9.CrossRefPubMed

44.

Wang S, Dong L, Wang X, Wang X. Classification of pathological types of lung cancer from CT images by deep residual neural networks with transfer learning strategy. Open Med (Wars). 2020;15:190–7. https://doi.org/10.1515/med-2020-0028.CrossRefPubMed

45.

Hawkins S, Wang H, Liu Y, Garcia A, Stringfield O, Krewer H, et al. Predicting malignant nodules from screening CT scans. J Thorac Oncol. 2016;11:2120–8. https://doi.org/10.1016/j.jtho.2016.07.002.CrossRefPubMedPubMedCentral

46.

Kim H, Park CM, Lee M, Park SJ, Song YS, Lee JH, et al. Impact of reconstruction algorithms on CT radiomic features of pulmonary tumors: analysis of intra- and inter-reader variability and inter-reconstruction algorithm variability. PLoS ONE. 2016;11:e0164924. https://doi.org/10.1371/journal.pone.0164924.CrossRefPubMedPubMedCentral

Title: Correlation analysis of clinical, pathological, imaging and genetic features of ground-glass nodule featured lung adenocarcinomas between high-risk and non-high-risk individuals
Authors: Jing Ren
Yuan Wang
Chunrong Liu
Lan Yang
Xinlu Men
Zhixin Qiu
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Lung Cancer
Lung Cancer
Lung Cancer
Published in: European Journal of Medical Research / Issue 1/2023
Electronic ISSN: 2047-783X
DOI: https://doi.org/10.1186/s40001-023-01462-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Correlation analysis of clinical, pathological, imaging and genetic features of ground-glass nodule featured lung adenocarcinomas between high-risk and non-high-risk individuals

Abstract

Background

Objectives

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Objectives

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2023

Seroprevalence of hepatitis C virus in Jinan, China, 2008–2020

Bidirectional association between infectious gastroenteritis and inflammatory bowel disease: a population-based study

Association of tirofiban treatment with outcomes following endovascular therapy in cardioembolic stroke: insights from the RESCUE BT randomized trial

Bacterial pathogens and in-hospital mortality in revision surgery for periprosthetic joint infection of the hip and knee: analysis of 346 patients

Identification of ANXA3 as a biomarker associated with pyroptosis in ischemic stroke

N7-methylguanosin regulators-mediated methylation modification patterns and characterization of the immune microenvironment in lower-grade glioma